A new case-control genetic study is reassuring in finding no association between a genetic proxy for pharmacologic PCSK9 inhibition and either heart failure or adverse cardiac remodeling in a large ...

Cardiovascular disease is the leading cause of death in the U.S. and around the world. Though it’s held the top spot for decades, it wasn’t always the king of mortal maladies. Its ascension was ...

Metastasis is responsible for 90 percent of cancer deaths. Researchers have found that the mutations driving it may stem from a commonly inherited variant of the PCSK9 gene. Metastasis is responsible ...

A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health ...

Somatic mutations emerge during tumour progression and can drive drug resistance. However, emergent somatic mutations driving metastasis have not been identified in tumour evolution sequencing. An ...

CRISPR-based therapies just hit another milestone. In a small clinical trial with 10 people genetically prone to dangerously high levels of cholesterol, a single infusion of the precision gene editor ...

Merck & Co. has completed a hat trick of phase 3 victories for its oral PCSK9 inhibitor. Navigating into the broader hyperlipidemia population, the drugmaker stayed out of the shoals and charted a ...

PCSK9 inhibitors are a type of medication that lowers cholesterol. Doctors may prescribe them to people alongside statins and other cholesterol-lowering drugs. Doctors commonly prescribe statins to ...